Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease

Recruiting now · Not applicable

Conditions studied: Charcot-Marie-Tooth Disease Type 1A

In brief

This is a 2-year follow-up study of a cohort of 35 CMT1A patients and 20 healthy volunteers. The main objective is identifying prognostic markers for CMT1A using multi-omics analysis. The study is recruiting subjects between the ages of 10 and 30. The most common inherited neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A), caused by a duplication of the gene expressing PMP22. CMT1A patients develop symptoms in early childhood with variable progression and there is no established therapy until now. Therapy must start in childhood, before peripheral nerves degenerate. However, we lack easily obtainable biomarkers in early disease stages. In CMT-MODs, we will identify disease and prognostic biomarkers in young CMT1A patients.

Key facts

Study ID
NCT07049588
Run by
Assistance Publique Hopitaux De Marseille
People needed
55
Starts
2025-06-24
Expected to finish
2028-06-24
Last updated by the study team
2025-07-03

Who can join

Age: 10 and older, up to 30. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.